Compare Iron Mountain Inc (IRM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Moderna, Inc. — how do they compare? Iron Mountain Inc trades at $113.75 (market cap $34.46B), while Moderna, Inc. trades at $213.06 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 2.3× Iron Mountain Inc's market cap, and Iron Mountain Inc pays a 2.99% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Moderna, Inc. for 59 Days on average.
| IRM | MRNA | |
|---|---|---|
Market Cap | $34.46B | $78.65B |
Volume | 1,379,608 | 37,373,437 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $203.46 |
52-Week Low | $78.86 | $22.36 |
Typical Hold Time | 80 Days | 59 Days |
Enterprise Value | $53.87B | $74.80B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong institutional interest. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent news highlights expansion in data centers and digital partnerships, including a 300MW pipeline and AI collaborations.
The outlook is supported by analyst consensus with a $142.75 price target (66.7% buy ratings), but high debt levels and elevated P/E of 82.09 pose risks. Earnings growth from digital initiatives is the key catalyst, while leverage and margin pressure require monitoring for sustained shareholder value.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
